<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30076411</PMID>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>04</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1476-5594</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                        <Day>03</Day>                    </PubDate>                </JournalIssue>                <Title>Oncogene</Title>                <ISOAbbreviation>Oncogene</ISOAbbreviation>            </Journal>            <ArticleTitle>Mouse ER+/PIK3CA<sup>H1047R</sup> breast cancers caused by exogenous estrogen are heterogeneously dependent on estrogen and undergo BIM-dependent apoptosis with BH3 and PI3K agents.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41388-018-0436-4</ELocationID>            <Abstract>                <AbstractText>Estrogen dependence is major driver of ER + breast cancer, which is associated with PI3K mutation. PI3K inhibition (PI3Ki) can restore dependence on ER signaling for some hormone therapy-resistant ER + breast cancers, but is ineffective in others. Here we show that short-term supplementation with estrogen strongly enhanced Pik3caH1047R-induced mammary tumorigenesis in mice that resulted exclusively in ER + tumors, demonstrating the cooperation of the hormone and the oncogene in tumor development. Similar to human ER + breast cancers that are endocrine-dependent or endocrine-independent at diagnosis, tumor lines from this model retained ER expression but were sensitive or resistant to hormonal therapies. PI3Ki did not induce cell death but did cause upregulation of the pro-apoptotic gene BIM. BH3 mimetics or PI3Ki were unable to restore hormone sensitivity in several resistant mouse and human tumor lines. Importantly however, combination of PI3Ki and BH3 mimetics had a profound, BIM-dependent cytotoxic effect in PIK3CA-mutant cancer cells while sparing normal cells. We propose that addition of BH3 mimetics offers a therapeutic strategy to markedly improve the cytotoxic activity of PI3Ki in hormonal therapy-resistant and ER-independent PIK3CA-mutant breast cancer.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Stratikopoulos</LastName>                    <ForeName>Elias E</ForeName>                    <Initials>EE</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kiess</LastName>                    <ForeName>Nicole</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Szabolcs</LastName>                    <ForeName>Matthias</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Columbia University Medical Center, New York, NY, 10032, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Pegno</LastName>                    <ForeName>Sarah</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kakit</LastName>                    <ForeName>Cheung</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wu</LastName>                    <ForeName>Xuewei</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Poulikakos</LastName>                    <ForeName>Poulikos I</ForeName>                    <Initials>PI</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cheung</LastName>                    <ForeName>Pamela</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Schmidt</LastName>                    <ForeName>Hank</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Parsons</LastName>                    <ForeName>Ramon</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. ramon.parsons@mssm.edu.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>SAC110028</GrantID>                    <Agency>Susan G. Komen for the Cure, Komen Wyoming Affiliate (Wyoming Affiliate of Susan G. Komen for the Cure)</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>CA129432</GrantID>                    <Agency>U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute (NCI)</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>03</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Oncogene</MedlineTA>            <NlmUniqueID>8711562</NlmUniqueID>            <ISSNLinking>0950-9232</ISSNLinking>        </MedlineJournalInfo>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>01</Month>                <Day>23</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>14</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>07</Month>                <Day>09</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>5</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>5</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>5</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30076411</ArticleId>            <ArticleId IdType="doi">10.1038/s41388-018-0436-4</ArticleId>            <ArticleId IdType="pii">10.1038/s41388-018-0436-4</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>